Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
This review provides practical insights to inform clinical practice and optimize personalized treatment plans for patients with metastatic breast cancer.
The art of sequencing therapy in the management of breast cancer is a multifaceted challenge requiring careful integration of clinical trial data, real‑world evidence, and individualized patient factors to guide treatment decisions.
Effective sequencing of therapies maximizes benefit, minimizes toxicity, and preserves future options for patients with metastatic breast cancer, addressing evolving resistance patterns and emerging targeted agents.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC
- Development of Herceptin resistance in breast cancer cells